Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

Blocking certain proteins can reduce skin inflammation caused by cancer treatment.

High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.

Baricitinib shows promise for treating alopecia areata with mild side effects.

Most children with CNS tumors on targeted therapy had skin reactions, which were generally treatable without stopping the therapy.

Metformin may help treat neuroendocrine tumors.

Keratinocytes can reduce the survival of certain melanoma cells, suggesting new therapy paths.

Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.

A new compound shows promise as a topical treatment for hair loss.

Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.

New treatments may restore cancer-blocking proteins, slow prostate cancer, identify drug targets, and potentially regrow hair.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

Breast cancer treatments work better with AR activation, improving results and reducing side effects.

Stopping mitochondrial respiration can prevent brain cancer spread in skin cancer patients, and plant compound β-sitosterol could help achieve this.

PRIDE complex side effects from EGFR inhibitors can be managed without stopping treatment.

A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.

EGFR inhibitors can cause skin issues, and managing these is important for treatment success.

Tofacitinib effectively and safely promotes hair regrowth in alopecia patients.

JAK inhibitors are effective and safe for treating severe alopecia areata.

Upadacitinib may effectively treat resistant lichen planopilaris.

JAK inhibitors show promise for treating various skin diseases.

ZD1839 can cause skin issues like acne and hair changes.

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

Tofacitinib may effectively treat folliculitis decalvans.